CN114209667A - 包含丙戊酸的延迟释放药物制剂和其用途 - Google Patents

包含丙戊酸的延迟释放药物制剂和其用途 Download PDF

Info

Publication number
CN114209667A
CN114209667A CN202111575415.8A CN202111575415A CN114209667A CN 114209667 A CN114209667 A CN 114209667A CN 202111575415 A CN202111575415 A CN 202111575415A CN 114209667 A CN114209667 A CN 114209667A
Authority
CN
China
Prior art keywords
vpa
pharmaceutically acceptable
acid
pai
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111575415.8A
Other languages
English (en)
Chinese (zh)
Inventor
尼尔斯·奥韦·古斯塔夫松
汉斯·罗格·马库斯·莫滕松
尼克拉斯·贝里
约纳斯·法耶尔松·萨廖
斯韦克·耶恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cereno Scientific AB
Original Assignee
Cereno Scientific AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cereno Scientific AB filed Critical Cereno Scientific AB
Publication of CN114209667A publication Critical patent/CN114209667A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202111575415.8A 2016-04-08 2017-04-10 包含丙戊酸的延迟释放药物制剂和其用途 Pending CN114209667A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1606197.0 2016-04-08
GB201606197 2016-04-08
CN201780025746.XA CN109414423A (zh) 2016-04-08 2017-04-10 包含丙戊酸的延迟释放药物制剂和其用途
PCT/GB2017/051002 WO2017175013A1 (en) 2016-04-08 2017-04-10 Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780025746.XA Division CN109414423A (zh) 2016-04-08 2017-04-10 包含丙戊酸的延迟释放药物制剂和其用途

Publications (1)

Publication Number Publication Date
CN114209667A true CN114209667A (zh) 2022-03-22

Family

ID=58709491

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780025746.XA Pending CN109414423A (zh) 2016-04-08 2017-04-10 包含丙戊酸的延迟释放药物制剂和其用途
CN202111575415.8A Pending CN114209667A (zh) 2016-04-08 2017-04-10 包含丙戊酸的延迟释放药物制剂和其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201780025746.XA Pending CN109414423A (zh) 2016-04-08 2017-04-10 包含丙戊酸的延迟释放药物制剂和其用途

Country Status (15)

Country Link
US (2) US11395808B2 (enExample)
EP (1) EP3439649B1 (enExample)
JP (1) JP6985368B2 (enExample)
KR (1) KR102438395B1 (enExample)
CN (2) CN109414423A (enExample)
AU (1) AU2017246697B2 (enExample)
CA (1) CA3018043A1 (enExample)
ES (1) ES2969021T3 (enExample)
HU (1) HUE064701T2 (enExample)
IL (1) IL262163B2 (enExample)
MX (1) MX395521B (enExample)
PL (1) PL3439649T3 (enExample)
RU (1) RU2760304C2 (enExample)
WO (1) WO2017175013A1 (enExample)
ZA (1) ZA201806766B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
PL3439649T3 (pl) 2016-04-08 2024-03-18 Cereno Scientific Ab Preparaty farmaceutyczne o opóźnionym uwalnianiu zawierające kwas walproinowy i ich zastosowanie
CN113995742B (zh) * 2021-10-22 2023-12-29 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 包含丙戊酸的美白组合物及其用途
GB2613900B (en) * 2021-12-20 2024-01-17 Cereno Scient Ab Novel compounds and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009737A1 (en) * 2007-07-12 2009-01-15 Neurosci, Inc. Sustained release formulation of active pharmaceuticals in a lipid based sustained release
CN101947209A (zh) * 2010-07-21 2011-01-19 河南中帅医药科技发展有限公司 双丙戊酸钠小丸及其制备方法
US20140051716A1 (en) * 2011-03-09 2014-02-20 Cereno Scientific Ab Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300111B1 (en) 1987-07-22 1991-10-16 Farvalsa AG A moisture stable solid valproic acid formulation and a method of preparing the same
WO2001022940A1 (en) * 1999-09-30 2001-04-05 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
AT408718B (de) * 1999-12-02 2002-02-25 Gerot Pharmazeutika Natriumvalproat-granulat mit verringerter hygroskopizität
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
JP2006507297A (ja) 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20040224006A1 (en) 2003-04-21 2004-11-11 Samn Raffaniello Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
US20050276848A1 (en) 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
WO2006117165A2 (en) 2005-05-02 2006-11-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Means and methods for the treatment of head injuries and stroke
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
AU2006287378A1 (en) 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by HDac inhibition
PL1937650T3 (pl) 2005-09-08 2011-11-30 Mei Pharma Inc Związki heterocykliczne
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
DE602006003848D1 (de) * 2006-01-11 2009-01-08 Teva Pharma Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate
WO2007084775A2 (en) 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
AU2007234380A1 (en) 2006-04-06 2007-10-11 Novartis Ag Combination of organic compounds
KR101468053B1 (ko) * 2006-08-31 2014-12-02 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
GB201003766D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
KR101892788B1 (ko) 2011-09-13 2018-08-28 파마싸이클릭스 엘엘씨 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
CN104248627A (zh) * 2013-06-25 2014-12-31 北大方正集团有限公司 丙戊酸半钠泡腾干混悬剂及其制备方法
GB201417828D0 (en) * 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
US20200179381A1 (en) 2016-04-08 2020-06-11 Cereno Scientific Ab Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
PL3439649T3 (pl) 2016-04-08 2024-03-18 Cereno Scientific Ab Preparaty farmaceutyczne o opóźnionym uwalnianiu zawierające kwas walproinowy i ich zastosowanie

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009737A1 (en) * 2007-07-12 2009-01-15 Neurosci, Inc. Sustained release formulation of active pharmaceuticals in a lipid based sustained release
CN101947209A (zh) * 2010-07-21 2011-01-19 河南中帅医药科技发展有限公司 双丙戊酸钠小丸及其制备方法
US20140051716A1 (en) * 2011-03-09 2014-02-20 Cereno Scientific Ab Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. DIANE BRUCE等: "Properties of enteric coated sodium valproate pellets", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 264, no. 1, pages 85 - 96, XP001180458, DOI: 10.1016/S0378-5173(03)00392-2 *

Also Published As

Publication number Publication date
RU2018137399A (ru) 2020-05-12
JP2019510834A (ja) 2019-04-18
IL262163A (en) 2018-11-29
JP6985368B2 (ja) 2021-12-22
RU2018137399A3 (enExample) 2020-06-18
US11395808B2 (en) 2022-07-26
ES2969021T3 (es) 2024-05-16
RU2760304C2 (ru) 2021-11-23
MX2018012224A (es) 2019-05-16
MX395521B (es) 2025-03-25
BR112018070626A2 (pt) 2019-02-05
WO2017175013A1 (en) 2017-10-12
IL262163B2 (en) 2023-07-01
EP3439649B1 (en) 2023-11-15
US12023311B2 (en) 2024-07-02
KR102438395B1 (ko) 2022-08-30
IL262163B1 (en) 2023-03-01
KR20180127480A (ko) 2018-11-28
EP3439649A1 (en) 2019-02-13
PL3439649T3 (pl) 2024-03-18
AU2017246697A1 (en) 2018-10-04
HUE064701T2 (hu) 2024-04-28
AU2017246697B2 (en) 2022-06-02
US20190111011A1 (en) 2019-04-18
CN109414423A (zh) 2019-03-01
CA3018043A1 (en) 2017-10-12
EP3439649C0 (en) 2023-11-15
ZA201806766B (en) 2024-03-27
NZ746269A (en) 2024-10-25
US20230120670A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
US20220401393A1 (en) Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
JP6480420B2 (ja) コルヒチンの徐放性製剤およびその使用方法
US12023311B2 (en) Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
HK1243921A1 (zh) 用於缓解尿频的延长释放制剂及其使用方法
US20230364089A1 (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
CN103889455A (zh) 稳定化乙哌立松医药组成物及含有上述组成物的缓释制剂
CZ298851B6 (cs) Tableta pro rízené podávání úcinných látek
KR20180054655A (ko) 연장, 지연 및 즉시 방출 제형 제조 방법 및 용도
JP6887043B2 (ja) コルヒチンの徐放性製剤およびその使用方法
BR112018070626B1 (pt) Formulação farmacêutica e uso da mesma
HK40004470B (en) Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
HK40086166A (zh) 丙戊酸的医疗用途
BR112014007876B1 (pt) Forma de dosagem, composição, processo para preparação de uma composição, uso de uma composição
HK1259497A1 (en) Composition for reducing the frequency of urination, method of making and use thereof
HK1245627A1 (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination